我们怀着浓厚的兴趣读了Laack和Hossfeld所写的关于非小细胞性肺癌(NSCLC)病人治疗的综述性文章。目前这样全面的综述并不多见。不过,该文忽视了一篇依我们看来是很重要的研究报道,即Cardenal等所写的与该文同一月发表,也是关于晚期NSCLC治疗的研究报道。在该研究中意大利的同道们采用半合成的长春碱类新药Vinorellbin对70岁和更年老的晚期NSCLC病人进行单种药物化疗,观察治疗病人生存质量的改善 We read with great interest the comprehensive review by Laack and Hossfeld about the treatment of patients with non-small cell lung cancer (NSCLC). Such a comprehensive review so far is rare. However, the article overlooks an article that seems to us to be of great importance in the same month published by Cardenal et al. And published in the same paper, which is also a report on the treatment of advanced NSCLC. In the study, fellow Italians used a single drug chemotherapy in patients with advanced NSCLC, aged 70 and older, using a semi-synthetic vinblastine-based new drug Vinorellbin to observe the improvement of patients’ quality of life